Fractyl Stock

fractyl.comHealthcare / BioTech & PharmaFounded: 2010Funding to Date: $572.96MM

Fractyl ais a biotechnology company looking to bring curative therapies to the large populations of patients with metabolic disease.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Fractyl before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Fractyl Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Fractyl Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
06/16/2021 Series F $100MM $xx.xx $872.9MM M28 Capital, Maverick Capital, Population Health Partners
Price per Share
$xx.xx
Shares Outstanding
11,927,048
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
M28 Capital, Maverick Capital, Population Health Partners
08/06/2020 Series E $55.07MM $xx.xx $378.52MM Bessemer Venture Partners, Catalio Capital Management, Cdib Venture Capital, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Mithril Capital Management, Taiwania Capital Management Corporation, True Ventures, Yj Capital
Price per Share
$xx.xx
Shares Outstanding
12,838,573
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Catalio Capital Management, Cdib Venture Capital, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Mithril Capital Management, Taiwania Capital Management Corporation, True Ventures, Yj Capital
11/30/2017 Series D $43.98MM $xx.xx $260.81MM Bessemer Venture Partners, Deerfield Management Company, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Ido Fund, Mithril Capital Management, True Ventures
Price per Share
$xx.xx
Shares Outstanding
11,994,461
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Deerfield Management Company, Domain Associates, Emergent Medical Partners, General Catalyst, Google Ventures, Ido Fund, Mithril Capital Management, True Ventures
11/19/2015 Series C-1 $20.26MM $xx.xx $169.58MM Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril
Price per Share
$xx.xx
Shares Outstanding
9,064,640
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril
11/19/2015 Series C-2 $47.17MM $xx.xx $169.58MM Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril
Price per Share
$xx.xx
Shares Outstanding
15,336,464
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bessemer Venture Partners, Deerfield Management Company, Domain Associates, General Catalyst, Mithril
03/21/2013 Series B $14.5MM $xx.xx $28.61MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
11,451,453
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/15/2011 Series A $5.5MM $xx.xx $11MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Leadership & Board

Leadership

Jay Caplan
President, Board Member & Co-Founder
Harith Rajagopalan Ph.D
Co-Founder, Chief Executive Officer and Board Member
Diane Marcou
Chief Financial Officer
Lisa Davidson
Chief Financial Officer
David Maggs
Chief Medical Officer

Board

Ajay Royan
Mithril Capital Management
Hemant Taneja
General Catalyst
William Bradley
Brian Dovey
Domain Associates
Christopher Gabrieli MD
Bessemer Venture Partners
Jay Caplan
Stanley Lapidus
Allan Will
Harith Rajagopalan Ph.D
John Amatruda

Fractyl stock FAQs

plusminus

Can you buy Fractyl stock?

You can no longer buy Fractyl stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Fractyl stock?

You can no longer buy Fractyl stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Fractyl stock?

You can no longer sell stock of Fractyl on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Fractyl stock?

You can no longer sell stock of Fractyl on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Fractyl a public company?

Fractyl is now a public company traded on NASDAQ with ticker GUTS.
plusminus

What is Fractyl’s stock price?

The stock price of Fractyl is not currently available.
plusminus

What is Fractyl’s stock ticker symbol?

The ticker symbol of Fractyl is GUTS.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Fractyl News and Media Highlights

Fractyl Sets Out $99M IPO Ambitions After Busy Week of Biotechs Going Public

Fractyl Health, a biotechnology startup that focuses on preventing and curing metabolic diseases, announced in December 2023 that an initial public offering (IPO) may happen for the company. The company is sticking to that plan by selling 7.3 million shares for $14 to $16 each to add $99 million in capital. Fractyl Health has tested its Rejuva gene therapy candidate, which is a treatment that may compete with semaglutide drug Wegovy from pharmaceutical researcher Novo Nordisk.

Fractyl Health Aims For $100 Million IPO Raise

Fractyl Health, which is a startup that designs medical therapies for metabolic health, filed with the SEC to raise $100 million through an initial public offering (IPO). Specifically, the Lexington, Massachusetts-based company is working to treat Type 2 Diabetes as well as obesity in patients, and Fractyl Health will use the IPO capital to complete its Revitalize-1 research, fund the Remain-1 study and development of Rejuva gene therapy candidates, and prepare for commercialization of its therapies.

Fractyl Completes $44M Series D Financing |FinSMEs

Fractyl Laboratories Inc., a Lexington, Mass.-based developer of minimally invasive procedural therapy that can reverse metabolic diseases, completed a $44m Series D financing. The round was led by an undisclosed new investor, joined by new investors GV, True Ventures, and the IDO Fund and returning investors General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital …
Browse Insights
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.